Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Waning Immunity after the BNT162b2 Vaccine in Israel
Yair Goldberg, Micha Mandel, Yinon M. Bar-On, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 669

Showing 1-25 of 669 citing articles:

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 16, pp. 1532-1546
Open Access | Times Cited: 2091
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Yinon M. Bar-On, Yair Goldberg, Micha Mandel, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1393-1400
Open Access | Times Cited: 1145
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
Daniel R. Feikin, Melissa M. Higdon, Laith J. Abu‐Raddad, et al.
The Lancet (2022) Vol. 399, Iss. 10328, pp. 924-944
Open Access | Times Cited: 1082
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
Victoria Hall, Sarah Foulkes, Ferdinando Insalata, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 13, pp. 1207-1220
Open Access | Times Cited: 621
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yu‐Ting Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 384
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Nick Andrews, Elise Tessier, Julia Stowe, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 4, pp. 340-350
Open Access | Times Cited: 379
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
Yair Goldberg, Micha Mandel, Yinon M. Bar-On, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 23, pp. 2201-2212
Open Access | Times Cited: 377
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 831-837
Open Access | Times Cited: 372
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
Sandile Cele, Laurelle Jackson, David S. Khoury, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 342
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study
Martina McMenamin, Joshua Nealon, Yun Lin, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 10, pp. 1435-1443
Open Access | Times Cited: 315
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
Edson Duarte Moreira, Nicholas Kitchin, Xia Xu, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 20, pp. 1910-1921
Open Access | Times Cited: 305
Covid-19 Vaccine Effectiveness in New York State
Eli S. Rosenberg, Vajeera Dorabawila, Delia Easton, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 2, pp. 116-127
Open Access | Times Cited: 300
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden
Peter Nordström, Marcel Ballin, Anna Nordström
The Lancet (2022) Vol. 399, Iss. 10327, pp. 814-823
Open Access | Times Cited: 278
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
Sam Afkhami, Michael R. D’Agostino, Ali Zhang, et al.
Cell (2022) Vol. 185, Iss. 5, pp. 896-915.e19
Open Access | Times Cited: 264
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100794-100794
Open Access | Times Cited: 260
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, et al.
Science (2021) Vol. 375, Iss. 6578, pp. 331-336
Open Access | Times Cited: 241
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
David Goldblatt, Galit Alter, Shane Crotty, et al.
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 6-26
Open Access | Times Cited: 233
SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
Stefan Pilz, Verena Theiler‐Schwetz, Christian Trummer, et al.
Environmental Research (2022) Vol. 209, pp. 112911-112911
Open Access | Times Cited: 232
The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good
Kevin Bardosh, Alexandre de Figueiredo, Rachel Gur‐Arie, et al.
BMJ Global Health (2022) Vol. 7, Iss. 5, pp. e008684-e008684
Open Access | Times Cited: 221
BNT162b2 Vaccine Booster and Mortality Due to Covid-19
Ronen Arbel, Ariel Hammerman, Ruslan Sergienko, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 26, pp. 2413-2420
Open Access | Times Cited: 217
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
Jia Wei, Koen B. Pouwels, Nicole Stoesser, et al.
Nature Medicine (2022) Vol. 28, Iss. 5, pp. 1072-1082
Open Access | Times Cited: 216
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Alessandro Sette, Shane Crotty
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 27-46
Open Access | Times Cited: 214
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
Matthew Gagné, Juan I. Moliva, Kathryn E. Foulds, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1556-1571.e18
Open Access | Times Cited: 208
COVID-19 mRNA vaccines: Platforms and current developments
Gábor Szabó, Azita J. Mahiny, Irena Vlatkovic
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1850-1868
Open Access | Times Cited: 194
Page 1 - Next Page

Scroll to top